Akers Biosciences (AKER) Reports FY17 Revenue of $3.93M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures rise on tech buying, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls as traders digest escalation in US-Iran strikes
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- SAP stock dips after Oracle's massive AI spending plans
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
Akers Biosciences Reports Earnings for Fiscal Year 2017
April 3, 2018 7:04 AM EDTTotal Revenue Up 33%
THOROFARE, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (Akers, Akers Bio or the "Company"), a developer of rapid health information technologies, reports its financial results for the fiscal year ended December 31, 2017.
2017 Financial Highlights:
Total revenue up 33% to $3,929,527 (2016: $2,960,912)PIFA Heparin/PF4 Rapid Assay products continue to account for the majority of revenues however, growth was driven primarily by BreathScan Alcohol Breathalyzers, BreathScan OxiChek and the re-introduced Tri-Cholesterol testTotal revenue up across all... More